Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Shares Purchased by Victory Capital Management Inc.

Victory Capital Management Inc. raised its stake in Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 58.7% during the third quarter, according to its most recent disclosure with the SEC. The fund owned 99,215 shares of the company’s stock after buying an additional 36,700 shares during the quarter. Victory Capital Management Inc.’s holdings in Amneal Pharmaceuticals were worth $825,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in AMRX. Vanguard Group Inc. lifted its stake in Amneal Pharmaceuticals by 0.6% in the first quarter. Vanguard Group Inc. now owns 13,728,233 shares of the company’s stock valued at $83,193,000 after buying an additional 85,846 shares during the last quarter. CANADA LIFE ASSURANCE Co raised its stake in shares of Amneal Pharmaceuticals by 417.8% during the first quarter. CANADA LIFE ASSURANCE Co now owns 36,106 shares of the company’s stock valued at $218,000 after purchasing an additional 29,133 shares in the last quarter. Price T Rowe Associates Inc. MD raised its stake in shares of Amneal Pharmaceuticals by 6.8% during the first quarter. Price T Rowe Associates Inc. MD now owns 81,264 shares of the company’s stock valued at $493,000 after purchasing an additional 5,146 shares in the last quarter. Bayesian Capital Management LP acquired a new position in Amneal Pharmaceuticals during the first quarter worth about $65,000. Finally, California State Teachers Retirement System grew its holdings in Amneal Pharmaceuticals by 5.4% during the first quarter. California State Teachers Retirement System now owns 122,504 shares of the company’s stock worth $742,000 after acquiring an additional 6,321 shares during the period. 31.82% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of research analysts recently issued reports on the company. Truist Financial lifted their target price on Amneal Pharmaceuticals from $10.00 to $12.00 and gave the stock a “buy” rating in a report on Wednesday, October 2nd. Barclays lifted their target price on Amneal Pharmaceuticals from $8.00 to $10.00 and gave the stock an “overweight” rating in a report on Tuesday, August 13th. JPMorgan Chase & Co. raised Amneal Pharmaceuticals from an “underweight” rating to a “neutral” rating and set a $9.00 target price on the stock in a report on Friday, September 6th. StockNews.com raised Amneal Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Monday, November 11th. Finally, Piper Sandler lifted their price target on Amneal Pharmaceuticals from $9.00 to $11.00 and gave the stock an “overweight” rating in a research note on Monday, November 11th. One investment analyst has rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $10.00.

Amneal Pharmaceuticals Trading Up 1.2 %

Shares of AMRX opened at $8.35 on Thursday. Amneal Pharmaceuticals, Inc. has a 1-year low of $4.16 and a 1-year high of $9.48. The business’s 50-day moving average price is $8.54 and its 200 day moving average price is $7.76. The stock has a market capitalization of $2.59 billion, a P/E ratio of -12.28 and a beta of 1.17.

Insider Buying and Selling at Amneal Pharmaceuticals

In other Amneal Pharmaceuticals news, SVP Jason B. Daly sold 43,657 shares of Amneal Pharmaceuticals stock in a transaction dated Friday, November 15th. The stock was sold at an average price of $8.61, for a total transaction of $375,886.77. Following the transaction, the senior vice president now owns 13,665 shares of the company’s stock, valued at $117,655.65. The trade was a 76.16 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. Company insiders own 17.46% of the company’s stock.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.